Progressive Supranuclear Palsy (PSP) represents the prototypical 4-repeat (4R) tauopathy, characterized by the preferential accumulation of hyperphosphorylated 4R tau isoforms in neurons and glia. Unlike Alzheimer's disease, which features an equal mixture of 3R and 4R tau isoforms, PSP demonstrates a selective predominance of 4R tau, reflecting distinct molecular pathophysiology[@dickinson2023]. This page synthesizes the molecular mechanisms underlying PSP tauopathy, including the basis for 4R tau aggregation, regional vulnerability patterns, glial pathology, and the relationship to related disorders including corticobasal degeneration (CBD) and corticobasal syndrome (CBS).
The pathogenesis of PSP involves a complex interplay of genetic predisposition (particularly the MAPT H1 haplotype), tau isoform dysregulation, post-translational modification abnormalities, and selective neuronal vulnerability. Understanding these mechanisms is essential for developing disease-modifying therapies targeting the core pathological process.
The microtubule-associated protein tau (MAPT) gene encodes six tau isoforms in the adult human brain through alternative splicing of exons 2, 3, and 10. Exclusion of exon 10 produces three-repeat (3R) isoforms, while inclusion produces four-repeat (4R) isoforms containing the third microtubule-binding repeat. In the normal adult brain, a 1:1 ratio of 3R:4R tau is tightly regulated to maintain physiological microtubule function[@dickinson2023].
In PSP, this balance is disrupted toward selective accumulation of 4R tau isoforms. This dysregulation occurs through multiple mechanisms:
Exon 10 splicing alterations: Mutations and polymorphisms in the MAPT gene can alter the splicing of exon 10, favoring inclusion and thereby increasing 4R tau production. The H1 haplotype, present in approximately 95% of PSP patients, is associated with altered splicing efficiency.
Reduced 3R tau clearance: Evidence suggests that 3R tau may be cleared more efficiently than 4R tau in PSP, contributing to the relative accumulation of 4R isoforms.
Cell-type specific splicing: Different neuronal populations demonstrate varying splicing efficiency for exon 10, potentially explaining selective vulnerability patterns.
Hyperphosphorylation of tau represents a central event in PSP pathogenesis. Phosphorylation at multiple sites reduces tau's microtubule-binding affinity, promotes its dissociation from microtubules, and facilitates aggregation into insoluble filaments.
While tau phosphorylation occurs across multiple sites in various tauopathies, PSP demonstrates distinct phosphorylation patterns:
| Phosphorylation Site | PSP Expression | CBD Expression | AD Expression |
|---|---|---|---|
| Ser356 (pS356) | +++ | + | - |
| Ser262 (pS262) | ++ | ++ | + |
| Ser396 (pS396) | ++ | + | +++ |
| Ser404 (pS404) | ++ | ++ | +++ |
| Thr181 (pT181) | + | + | +++ |
The phosphorylation at Serine 356 represents the most PSP-specific marker, present in the majority of PSP cases but largely absent from other tauopathies[@dickinson2023]. This site is located in the second microtubule-binding repeat and shows strong correlation with markers of inflammation and apoptosis.
The aggregation of tau into filamentous structures follows a nucleation-dependent process:
Oligomeric intermediates: Small oligomers (dimers, trimers) form before mature fibrils. In PSP, these oligomers demonstrate enhanced seeding potency compared to other tauopathies.
Primary nucleation: Spontaneous formation of tau aggregates from soluble tau, facilitated by hyperphosphorylation and reduced O-GlcNAcylation.
Secondary nucleation: Existing fibrils catalyze new fibril formation through surface-catalyzed nucleation, enabling propagation[@dickinson2023].
Filament elongation: Addition of tau monomers to fibril ends, resulting in the characteristic straight filaments observed in PSP.
The resulting filaments demonstrate distinct morphology from the paired helical filaments seen in Alzheimer's disease—straight, non-twisted filaments with C-shaped protofilament cores.
The subthalamic nucleus (STN) is a small, lens-shaped structure located in the basal ganglia, dorsal to the substantia nigra. It plays a critical role in motor control by providing excitatory (glutamatergic) input to the internal segment of the globus pallidus (GPi), thereby modulating the indirect motor pathway[@falzone2022].
In PSP, the subthalamic nucleus demonstrates early and severe involvement, contributing to the characteristic motor phenotype:
Several factors may contribute to the selective vulnerability of the subthalamic nucleus in PSP:
High metabolic demand: The STN has among the highest cerebral metabolic rates in the brain, potentially creating vulnerability to energy failure.
Glutamatergic excitotoxicity: The excitatory nature of STN outputs may render it vulnerable to excitotoxic damage.
Network connectivity: The STN receives extensive inputs from multiple brain regions affected in PSP, including the cortex, pedunculopontine nucleus, and substantia nigra.
Iron accumulation: The STN demonstrates high iron content, and iron-catalyzed oxidative stress may promote tau pathology[@falzone2022].
The early involvement of the subthalamic nucleus contributes to several core PSP features:
Deep brain stimulation of the STN has been explored as a therapeutic approach in PSP, though results have been mixed due to the diffuse nature of pathology.
Tufted astrocytes represent a defining glial pathological feature of PSP, distinct from the astrocytic plaques seen in corticobasal degeneration. These tau-positive glial inclusions are characterized by:
The formation of tufted astrocytes involves several overlapping mechanisms:
Astrocytic tau uptake: Astrocytes can internalize extracellular tau through endocytosis, particularly via membrane-bound tau species.
Impaired degradation: Both the ubiquitin-proteasome system and autophagy-lysosomal pathways are impaired in PSP astrocytes, leading to tau accumulation.
Cellular stress responses: Oxidative stress, mitochondrial dysfunction, and neuroinflammation promote tau aggregation within astrocytes.
Astrocyte reactivity: Reactive astrocytes demonstrate enhanced tau uptake and reduced clearance capacity[@gutman2023].
Tufted astrocytes contribute to PSP pathogenesis through multiple mechanisms:
PSP and CBD share the 4R tauopathy classification but demonstrate important distinctions[@levin2022]:
| Feature | PSP | CBD |
|---|---|---|
| Primary tau isoform | 4R | 4R |
| Filament morphology | Straight filaments | Mixed straight/twisted |
| Astrocytic pathology | Tufted astrocytes | Astrocytic plaques |
| Neuronal loss pattern | Brainstem predominant | Cortical predominant |
| Key clinical difference | Vertical gaze palsy | Apraxia |
Despite both being classified as 4R tauopathies, emerging evidence indicates distinct molecular mechanisms:
Corticobasal Syndrome (CBS) represents a clinical syndrome that can arise from multiple underlying pathologies, including PSP and CBD. This clinicopathological dissociation has important implications:
This overlap underscores the importance of biomarker development for distinguishing underlying pathologies in life.
Despite differences, PSP, CBD, and related 4R tauopathies share common pathogenic mechanisms:
Tau pathology propagates through neural networks in a prion-like manner:
The progression of tau pathology in PSP follows a characteristic anatomical pattern:
This spreading pattern correlates with clinical progression, from early brainstem and basal ganglia features to later cortical involvement.
Understanding the molecular mechanisms of PSP tauopathy has identified several therapeutic targets:
| Target | Strategy | Status |
|---|---|---|
| Tau aggregation | Small molecule inhibitors | Phase 1-2 |
| Tau clearance | Immunotherapies | Phase 2-3 |
| Tau phosphorylation | Kinase inhibitors | Research |
| 4R tau production | ASO-mediated splicing | Preclinical |
| Neuroinflammation | Anti-inflammatory agents | Research |
Molecular mechanisms inform biomarker development:
The recognition of distinct mechanisms in PSP vs. CBD has implications for precision medicine: